SquareMind raised $18M to deploy Swan, a robot that performs automated full body dermoscopy using a robotic arm and AI triage to flag suspicious skin lesions. The company's claims of FDA clearance appear unsupported in public FDA databases despite multiple queries, raising…
SquareMind, a Paris-based robotics startup, has raised $18 million to deploy a robot that takes full-body photographs of your skin in minutes, without a doctor in the room, and uses AI to flag anything that looks like cancer. The company calls Swan the world's first robot for full-body dermoscopy, according to The Robot Report. It says the device is FDA-listed and CE-marked, cleared for commercial use in the United States and Europe. That is what the company says.
What the FDA's public database says is harder to pin down. A search of the agency's 510(k) clearance database for SquareMind, Swan, and related terms did not surface a matching clearance record. The company's press release describes Swan as "FDA-listed," but the public record that would confirm exactly what the device is cleared to do, what its indicated uses are, what testing was submitted, what limitations were placed on its authorization was not found in multiple queries of the FDA's databases. SquareMind did not respond to a request for the specific 510(k) number before publication.
That gap matters. Full-body dermoscopy at dermoscopic resolution is not a trivial claim. A dermatoscope is a dermatologist's magnifying glass with polarized light. It turns a suspicious mole into a viewable, classifiable lesion. Doing that across an entire body in minutes, with a robot arm and AI triage on the back end, is a fundamentally different product than a handheld dermatoscope. If Swan got clearance as an augmented dermatoscope, that's one thing. If it got clearance as an autonomous diagnostic tool, that's another. The difference is everything.
Fred Moll is betting on the former. Moll founded Intuitive Surgical, the company that built the da Vinci surgical system, and later co-founded Sonder Capital, the San Francisco venture firm that led this funding round. His involvement is the kind of credential that makes investors and clinicians take a meeting. It also means SquareMind has been around long enough to have done the regulatory work, but not necessarily that the work is done.
The clinical logic behind Swan is sound. Skin cancer is the most common cancer in the United States, and melanoma is most deadly when it's caught late. Eighty percent of melanomas arise as new lesions, not as evolutions of existing moles. That means the watch your existing moles advice dermatologists give has always been incomplete. To catch the dangerous new ones, you need a full-body baseline for comparison. Getting a dermatologist to do one takes months and a specialist visit. Swan is designed to do it in minutes, at machine-consistent quality, with AI helping prioritize what the doctor looks at first.
The broader market pressure is real. Dermatology waitlists stretch months in most major health systems. Skin screening is the highest-volume procedure in the specialty. The AI-Driven Tele-Dermatoscope market is projected to reach $4.06 billion by 2029, a figure that tells you every digital health investor is looking at the same opportunity. FotoFinder, a German company, already sells a dermoscopy system with an AI assistant called AIMEE. SkinVision and Skin Analytics have smartphone-based triage tools. Canfield Scientific sells the imaging systems most dermatology practices already use.
What Swan adds is autonomy and speed. The robot handles positioning and image acquisition. The AI handles prioritization. The dermatologist handles the final read. The company describes it as a workflow tool, not a replacement for clinical judgment. That framing, which automates the photograph not the diagnosis, is the one that makes regulatory sense. It is also, not coincidentally, the one that is hardest to verify from a press release.
SquareMind has $18 million to figure out the difference. The money comes from Sonder Capital, the Deeptech 2030 Fund managed by Bpifrance on behalf of the French government, and Adamed Technology. The round includes previously undisclosed pre-Series A financing. The company says Swan is installed or being installed at pilot sites in the US and Europe.
Whether those deployments are happening under a genuine FDA clearance or something more provisional is the question the company has not yet answered publicly. It is also the question that will determine whether Swan is a robotics story or a regulatory compliance story. Right now, it's both.